Fig. 2From: Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in EuropeFIX treatment utilisation and costs by country. EHL, extended half-life; IU, international units; SHL, short half-lifeBack to article page